ADPT Stock Recent News

Medicine is not always simple. A drug that cures one patient can easily kill another, based on anything from their weight to their genes to anything else.

SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 2023 RBC Capital Markets Global Healthcare Conference in New York, New York.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-founder, Chairman & Chief Executive Officer Tycho Peterson - Chief Financial Officer Nitin Sood - Chief Commercial Officer, MRD Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Derik De Bruin - Bank of America Yuko Oku - Morgan Stanley Tom Stevens - Cowen & Company Dustin Scaringe - William Blair Elizabeth Webster - Goldman Sachs Dan Leonard - Credit Suisse Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2023 Conference Call.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago.

Here is how Adaptive Biotechnologies (ADPT) and Avanos Medical (AVNS) have performed compared to their sector so far this year.

SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

The consensus price target hints at a 49.9% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here is how Adaptive Biotechnologies (ADPT) and Geron (GERN) have performed compared to their sector so far this year.

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Adaptive Biotechnologies (ADPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2022 Earnings Conference Call February 14, 2023 4:30 PM ET Corporate Participants Karina Calzadilla - VP, Investor Relations Tycho Peterson - Chief Financial Officer Sharon Benzeno - Chief Commercial Officer, Immune Medicine Nitin Sood - Chief Commercial Officer, MRD Chad Robins - Co-founder, Chairman and Chief Executive Officer Conference Call Participants Derik De Bruin - Bank of America David Westenberg - Piper Sandler Daniel Brennan - Cowen Julia Cheng- JPMorgan Mark Massaro - BTIG Elizabeth Webster - Goldman Sachs Andrew Brackmann - William Blair Sung Ji Nam - Scotia Bank Dan Leonard - Credit Suisse Operator Good day and thank you for standing by and welcome to the Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions].